AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-01 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
D-Ribose-L-cysteine functions as a cysteine prodrug, delivering cysteine in a chemically protected form that may resist premature oxidation. After cellular uptake, enzymatic cleavage releases free L-cysteine, which can then enter the γ-glutamyl cycle for glutathione synthesis. This mechanism differs from N-acetylcysteine, which relies on de-acetylation and exhibits different absorption and metabolic characteristics. While both compounds ultimately increase cysteine availability, direct comparative data in humans remain limited. D-Ribose-L-cysteine is regulated in the United States as a dietary supplement ingredient, not as a pharmaceutical drug. Products containing D-ribose-L-cysteine are subject to dietary supplement regulations under the Dietary Supplement Health and Education Act of 1994 (DSHEA), which prohibit claims that a product can diagnose, treat, cure, or prevent disease. No pharmaceutical drug approvals or therapeutic indications have been granted for D-ribose-L-cysteine by the U.S. Food and Drug Administration.
=== They Hunger === In the first episode, the player takes the role of a troubled writer who has gone to a country retreat to work on his next masterpiece. However, the player soon hears the news over the radio of 'strange atmospheric phenomena', and his car crashes into a lake after being struck by a lightning bolt. Severely wounded and armed only with a recharging flashlight, the player moves out to find help. His only means of escaping the lake is by swimming through a drainage pipe into a maze of catacombs. He comes to a mortuary chapel and finds an umbrella and medkits to heal himself with. Along the way, he's had several disturbing experiences: an unfinished catacomb is empty and has a splash of blood near it. The pathways are echoing screams of the damned. A bloodied skull rolls out of an ossuary, and as he enters the chapel, he hears someone screaming "No! No! Get it off me!", from who he takes his umbrella. As soon as he starts to leave, strange things start happening. A zombie breaks through a coffin and starts chasing him. The player has to smash the zombie down with the handle of the umbrella he took. He climbs the ladder to the church bell, only to find hostile headcrab-like creatures and a dead body. He takes a silenced 9mm Beretta pistol and rings the church bell for help. A vent opens and he climbs in to find some dynamite.
=== Increases in federal funding === On June 17, 1971, Nixon held a press conference in which he announced, "America's public enemy number one in the United States is drug abuse." He continued, "In order to fight and defeat this enemy, it is necessary to wage a new, all-out offensive." In the speech, Nixon called for Congress to approve the allocation of $150 million in new funding to the "treatment and prevention of drug abuse." According to the Bureau of Labor Statistics, that is now the equivalent of just under $966 million.
Sources: en.wikipedia.org
is a parameter which measures the steepness of the power-law rise of the ascending flank of the first peak of the radial distribution function, and is quantitatively related to the repulsive part of the interatomic potential. Finally,
Pardee (1912), neurologist, husband of Abby Rockefeller Alfred Sturtevant (1912), geneticist, protege of Thomas Hunt Morgan and winner of the National Medal of Science James Chapin (1916), ornithologist; 17th president of The Explorers Club Seeley G. Mudd (1917), physician and philanthropist, former dean of Keck School of Medicine of USC Harold Alexander Abramson (1919), early advocate of Psychedelic therapy Augustus Braun Kinzel (1919), metallurgist and first president of the National Academy of Engineering William V. Silverberg (1919), founder of the American Academy of Psychoanalysis and Dynamic Psychiatry Sherman Fairchild* (1920), founder of Fairchild Aircraft, Fairchild Industries, Fairchild Camera and Instrument as well as Fairchild Semiconductor Francis Bitter (1925), physicist, inventor of Bitter electromagnets Howard Bruenn (1925), personal physician to Franklin D. Roosevelt Albert Charles Smith (1926), botanist, former director of the National Museum of Natural History and the Arnold Arboretum Konrad Lorenz* (1926), winner of the Nobel Prize in Physiology or Medicine Jerrold R. Zacharias (1926), nuclear physicist, professor at Massachusetts Institute of Technology Andrew Streitwieser (1927), chemist known for his contributions to physical organic chemistry Julian M. Sturtevant (1927), chemist at Yale University Raymond D.
=== Air purifier distribution === On Friday, July 21, 2023, Illinois Governor JB Pritzker and the Illinois Department of Public Health announced they were partnering with SHIELD Illinois to distribute air purifiers to licensed Illinois Day Care outside of the city of Chicago. The purifiers were purchased with $10 million of federal funds through the CDC's Epidemiology and Laboratory Capacity for Prevention and Control (ELC) Reopening Schools Program. SHIELD Illinois will use the extensive logistics capabilities developed serving over 2,300 locations during the pandemic to distribute the filters across the state.
Sources: en.wikipedia.org
=== Antioxidants === The skin contains several antioxidants, including vitamin E, coenzyme Q10, ascorbate, carotenoids, superoxide dismutase, catalase, and glutathione peroxidase. These antioxidants provide protection from reactive oxygen species produced during normal cellular metabolism. However, overexposure to UV rays can lead to a significant reduction in the antioxidant supply, thus increasing oxidative stress. Hence, these antioxidants are essential in the skin's defense mechanism against UV radiation and photocarcinogenesis.
Collagen alpha-1(IV) chain (COL4A1) is a protein that in humans is encoded by the COL4A1 gene on chromosome 13. It is ubiquitously expressed in many tissues and cell types. COL4A1 is a subunit of the type IV collagen and plays a role in angiogenesis. Mutations in the gene have been linked to diseases of the brain, muscle, kidney, eye, and cardiovascular system. The COL4A1 gene also contains one of 27 SNPs associated with increased risk of coronary artery disease.
== Predicted properties == Very few properties of rutherfordium or its compounds have been measured; this is due to its extremely limited and expensive production and the fact that rutherfordium (and its parents) decays very quickly. A few singular chemistry-related properties have been measured, but properties of rutherfordium metal remain unknown and only predictions are available.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.